Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Radiation for Recurrent Prostate Cancer
NCT00480857Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2007
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percentage of Patients Alive Without Progression at 4 years. Started Mar 2007; status: terminated.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00480857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480857.